Latest news with #Bayko
Business Insider
07-06-2025
- Business
- Business Insider
Vera Therapeutics (VERA) Gets a Buy from Evercore ISI
In a report released today, Liisa Bayko from Evercore ISI reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $75.00. The company's shares opened today at $21.27. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bayko is a 4-star analyst with an average return of 7.6% and a 44.00% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Altimmune, Vertex Pharmaceuticals, and Intellia Therapeutics. Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $67.36, implying a 216.76% upside from current levels. In a report released today, TD Cowen also reiterated a Buy rating on the stock with a $60.00 price target.
Business Insider
31-05-2025
- Business
- Business Insider
Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of $48.00. The company's shares closed yesterday at $7.45. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bayko is a 4-star analyst with an average return of 5.9% and a 40.98% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Altimmune, Vertex Pharmaceuticals, and Intellia Therapeutics. In addition to Evercore ISI, Intellia Therapeutics also received a Buy from JonesTrading's Debanjana Chatterjee in a report issued today. However, yesterday, J.P. Morgan maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA). The company has a one-year high of $28.18 and a one-year low of $5.90. Currently, Intellia Therapeutics has an average volume of 3.83M.
